Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib

J Gastrointest Cancer. 2019 Sep;50(3):601-603. doi: 10.1007/s12029-018-0067-6.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Ammonia / blood
  • Anti-Bacterial Agents / therapeutic use
  • Anticonvulsants / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Female
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / pathology
  • Humans
  • Hyperammonemia / chemically induced*
  • Hyperammonemia / diagnosis
  • Hyperammonemia / drug therapy
  • Indazoles
  • Middle Aged
  • Neurotoxicity Syndromes / diagnosis
  • Neurotoxicity Syndromes / drug therapy
  • Neurotoxicity Syndromes / etiology*
  • Phenylurea Compounds / adverse effects
  • Protein Kinase Inhibitors / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyridines / adverse effects
  • Pyrimidines / adverse effects
  • Sulfonamides / adverse effects
  • Sunitinib / adverse effects
  • Treatment Outcome
  • Withholding Treatment

Substances

  • Anti-Bacterial Agents
  • Anticonvulsants
  • Indazoles
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrimidines
  • Sulfonamides
  • regorafenib
  • Ammonia
  • pazopanib
  • Protein-Tyrosine Kinases
  • Sunitinib